SCHEMBL1748589

SCHEMBL1748589

C[Si](C)(C)C#Cc1cc(F)cnc1N

nearest known ligand 0.34

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1713842 0.81 NOS3 (0.50) NOS3NOS1NOS2
SCHEMBL2039210 0.81 NOS3 (0.32) NOS3NOS1NOS2
SCHEMBL30875153 0.79
SCHEMBL1665941 0.79 CSF1R (0.39) NOS3NOS1NOS2
SCHEMBL22400560 0.79 AGBL2 (0.30)
SCHEMBL24869418 0.79
SCHEMBL2637090 0.79 KMT2A (0.47) NOS3NOS1NOS2
SCHEMBL15055583 0.79
SCHEMBL1714544 0.78 ALDH1A1 (0.39) NOS3NOS1NOS2
SCHEMBL18236353 0.78 HTT (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180134730-A1 IMPROVED PROCESS FOR PREPARING BORYL 7-AZAINDOLE COMPOUNDS BOROPHARM INC (US) 2018-05-17 US claimed
WO-2016191079-A1 IMPROVED PROCESS FOR PREPARING BORYL 7-AZAINDOLE COMPOUNDS BOROPHARM, INC. (US) 2016-12-01 WO claimed
US-12357631-B2 Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication COCRYSTAL PHARMA, INC. (US) 2025-07-15 US disclosed
EP-3829719-B1 PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION COCRYSTAL PHARMA INC (US) 2025-04-02 EP disclosed
US-20240360165-A1 INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) MEDIC LIFE SCIENCES, INC. 2024-10-31 US disclosed
CN-112638477-B Pyrrolo [2,3-B ] pyridine derivatives as inhibitors of influenza virus replication 共晶制药公司 2024-01-26 CN disclosed
EP-4295852-A2 PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) Syros Pharmaceuticals, Inc. (US) 2023-12-27 EP disclosed
US-20230339943-A1 ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVES Guangdong Raynovent Biotech Co., Ltd. (CN) 2023-10-26 US disclosed
US-11725009-B2 Anti-influenza virus pyrimidine derivative Guangdong Raynovent Biotech Co., Ltd. (CN) 2023-08-15 US disclosed
US-11725009-B2 Anti-influenza virus pyrimidine derivative Guangdong Raynovent Biotech Co., Ltd. (CN) 2023-08-15 US disclosed
EP-3484871-B1 PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS INC (US) 2023-06-07 EP disclosed
US-20080090834-A1 SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS PFIZER INC 2008-04-17 US disclosed
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-02-21 US disclosed
WO-2008004117-A1 SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS PFIZER PRODUCTS INC. (US) 2008-01-10 WO disclosed
EP-1799691-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2007-06-27 EP disclosed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US disclosed
EP-1732546-A2 NOVEL PYRROLO (2,3-B)PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS Aventis Pharma S.A. (FR) 2006-12-20 EP disclosed
US-20060183758-A1 Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans CB RESEARCH AND DEVELOPMENT, INC. (US) 2006-08-17 US disclosed
WO-2006037875-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2006-04-13 WO disclosed
WO-2005095399-A2 NOVEL PYRROLO (2,3-B)PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11725009-B2 Anti-influenza virus pyrimidine derivative ENTPD5, NUDT15, ITPA NOS3 2723/4885NOS1 2918/4885NOS2 2859/4885
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors BRSK2, KSR2, CDK2 NOS3 953/4885NOS1 1002/4885NOS2 916/4885
US-20060183758-A1 Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans TPMT, INMT, AANAT NOS3 592/4885NOS1 951/4885NOS2 685/4885
US-20080090834-A1 SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS PDE5A, PDE3B, PDE12 NOS3 106/4885NOS1 137/4885NOS2 125/4885
US-20180134730-A1 IMPROVED PROCESS FOR PREPARING BORYL 7-AZAINDOLE COMPOUNDS AZI2, BCCIP, ADAR NOS3 2667/4885NOS1 3373/4885NOS2 2978/4885
US-20240360165-A1 INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) CDK7, CDK3, CDK9 NOS3 3001/4885NOS1 2697/4885NOS2 2986/4885
US-20230339943-A1 ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVES ENTPD5, NUDT1, ITPA NOS3 2801/4885NOS1 2937/4885NOS2 2899/4885
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors MAP3K19, MAP4K2, MAP3K1 NOS3 1315/4885NOS1 1773/4885NOS2 1724/4885
US-12357631-B2 Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication PIR, PNPO, IDO1 NOS3 1994/4885NOS1 1889/4885NOS2 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.